Ovid Therapeutics Inc. (OVID) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 1.58M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.58M | (m) | (m) |
| 2026-03-31 | (m) | $7.12M | (m) | (m) |
| 2025-12-31 | (m) | $7.25M | (m) | (m) |
| 2025-09-30 | (m) | $6.61M | (m) | (m) |
| 2025-06-30 | (m) | $6.65M | (m) | (m) |
| 2025-03-31 | (m) | $548.00K | (m) | (m) |
| 2024-12-31 | (m) | $566.00K | (m) | (m) |
| 2024-09-30 | (m) | $631.70K | (m) | (m) |
| 2024-06-30 | (m) | $567.70K | (m) | (m) |
| 2024-03-31 | (m) | $473.69K | (m) | (m) |
| 2023-12-31 | (m) | $391.69K | (m) | (m) |
| 2023-09-30 | (m) | $296.41K | (m) | (m) |
| 2023-06-30 | (m) | $198.54K | (m) | (m) |
| 2023-03-31 | (m) | $123.54K | (m) | (m) |
| 2022-12-31 | (m) | $1.50M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $208.38M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |